

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in this application:

Claims 1-10 (cancelled).

Claim 11 (currently amended). An aptamer comprising a first nucleic acid sequence that binds to a first target and a second nucleic acid sequence that binds to a second target, wherein the second sequence is an immunostimulatory CpG motif that stimulates an immune response, wherein the CpG motif comprises the formula rCGyy, wherein "r" is a purine, "C" is cytosine, "G" is guanosine and "y" is a pyrimidine, and wherein the first sequence binds to a first target selected from the group consisting of PDGF, IgE, IgE Fc ϵ R1, prostate-specific membrane antigen (PSMA), CD22, TNF-alpha, CTLA4, PD-1, PD-L1, PD-L2, FcRIIB, BTLA, transmembrane protein containing immunoglobulin and mucin-like domains (TIM-3), CD11c, B lymphocyte activating factor (BAFF), B7-X, CD19, CD20, CD25 and CD33.

Claims 12-13 (cancelled).

Claim 14 (previously presented). A pharmaceutical composition comprising the aptamer of claim 11, a cytotoxic agent and a pharmaceutically acceptable carrier.

Claim 15 (previously presented). The composition of claim 14, wherein the cytotoxic agent belongs to a class of cytotoxic agents selected from the group consisting of tubulin

stabilizers, tubulin destabilizers, anti-metabolites, purine synthesis inhibitors, nucleoside analogs, DNA alkylating agents, DNA modifying agents and vascular disrupting agents.

Claim 16 (previously presented). The composition of claim 14, wherein the cytotoxic agent is selected from the group consisting of calicheamycin, doxorubicin, taxol, methotrexate, gemcitabine, cytarabine, vinblastin, daunorubicin, docetaxel, irinotecan, epothilone B, epothilone D, cisplatin, carboplatin and 5-fluoro-U.

Claims 17-64 (cancelled).